Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
Levi & Korsinsky Announces an Investigation on Behalf of Sangamo Therapeutics, Inc. (SGMO) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Hosted on MSN7d
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, ...
Why did Pfizer's exit from gene therapy program hit Sangamo hard?
Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...
Benzinga.com7d
9 Analysts Have This To Say About Sangamo Therapeutics
9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...
Business Wire4d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leadi…
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
Sangamo Therapeutics: Left At The Alter (Rating Downgrade)
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Yahoo Finance3d
PFE Returns Rights to Hemophilia A Candidate to Partner SGMO
SGMO’s stock crashed on the news. Sangamo is considering all options to continue the program, which includes looking for a new collaboration partner for the candidate. In July, the companies ...
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...
Yahoo Finance3d
Sangamo Therapeutics, Inc. (SGMO)
RICHMOND, Calif., October 22, 2024--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...